Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyrotinib - Jiangsu Hengrui Medicine

Drug Profile

Pyrotinib - Jiangsu Hengrui Medicine

Alternative Names: BLTN; Pyrroltinib maleate; SHR 1258

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Chinese Academy of Medical Sciences; Jiangsu Hengrui Medicine Co.; Shanghai Changzheng Hospital; Tongji University
  • Class Antineoplastics; Pyridines; Pyrrolidines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Breast cancer
  • Phase III Non-small cell lung cancer
  • Phase I Gastric cancer
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 10 Jan 2020 Qingdao Zhixin Health Technology plans a phase I/II trial for Colorectal cancer (Combination therapy, Metastatic diease, Second-line therapy or greater) in China (NCT04227041)
  • 27 Nov 2019 Jiangsu HengRui Medicine plans the phase II Basket trial for Solid tumours (Late-stage disease) in China (PO) in December 2019 (NCT04179656)
  • 19 Sep 2019 Jiangsu HengRui Medicine Co. initiates a phase-II clinical trials in Breast cancer (Second-line therapy or greater, Treatment-experienced, Metastatic disease, Combination therapy, Inoperable/Unresectable) in China (PO) (NCT04095390)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top